Liu Jinshen, Liu Yan, Sun Jie, Guo Yuying, Lei Yuxin, Guo Mingyi, Wang Linhong
North China University of Science and Technology Affiliated Hospital, 73 Jianshe South Road, Lubei District, Tangshan City 062000, Hebei Province, China.
North China University of Science and Technology Affiliated Hospital, 73 Jianshe South Road, Lubei District, Tangshan City 062000, Hebei Province, China.
Biomed Pharmacother. 2023 Dec;168:115726. doi: 10.1016/j.biopha.2023.115726. Epub 2023 Oct 18.
Momordica charantia polysaccharide (MCP) is a potential drug for the prevention and alleviation of diabetes mellitus (DM) and diabetic retinopathy (DR). This study aimed to investigate the potential protective effects of MCP on early-stage DR and explore the underlying mechanisms. The model group (DM group) and treatment group (D+H group) were established by inducing type 1 DM using a single dose of streptozotocin (STZ) at 60 mg/kg. After modeling, the D+H group was orally administered a 500 mg/kg dose of MCP solution once daily for 12 weeks. Monitoring of systemic indicators (FBG, body weight, general condition) and retinal tissue inflammation and apoptosis (HE staining, IL-6, MCP-1, TNF-α, VEGF, NF-κB, Caspase-3) in this study demonstrated that MCP intervention alleviated both DM and DR. MCP improved the body weight and general condition of DM rats by reducing FBG levels. It also enhanced the anti-inflammatory and anti-apoptotic capabilities of retinal neurons and microvessels by modulating the actions of cytokines, thereby further regulating the inflammation and apoptosis of retinal neurons and microvessels. The underlying mechanisms may be associated with the downregulation of NF-κB and Caspase-3 pathway protein expression, as well as the downregulation of mRNA expression of NF-κB and Caspase-3 pathway genes. Further research is needed to elucidate the potential mechanisms underlying the protective effects of MCP on DR. MCP may emerge as a selective medication for the prevention and alleviation of DM and a novel natural medicine for the prevention and alleviation of DR.
苦瓜多糖（MCP）是一种预防和缓解糖尿病（DM）及糖尿病视网膜病变（DR）的潜在药物。本研究旨在探讨MCP对早期DR的潜在保护作用，并探索其潜在机制。通过以60mg/kg的单剂量链脲佐菌素（STZ）诱导1型糖尿病建立模型组（DM组）和治疗组（D+H组）。建模后，D+H组每天口服一次500mg/kg剂量的MCP溶液，持续12周。本研究对全身指标（空腹血糖、体重、一般状况）以及视网膜组织炎症和凋亡（苏木精-伊红染色、白细胞介素-6、单核细胞趋化蛋白-1、肿瘤坏死因子-α、血管内皮生长因子、核因子-κB、半胱天冬酶-3）进行监测，结果表明MCP干预可缓解DM和DR。MCP通过降低空腹血糖水平改善了DM大鼠的体重和一般状况。它还通过调节细胞因子的作用增强了视网膜神经元和微血管的抗炎和抗凋亡能力，从而进一步调节视网膜神经元和微血管的炎症和凋亡。潜在机制可能与核因子-κB和半胱天冬酶-3信号通路蛋白表达的下调以及核因子-κB和半胱天冬酶-3信号通路基因mRNA表达的下调有关。需要进一步研究以阐明MCP对DR保护作用的潜在机制。MCP可能成为预防和缓解DM的选择性药物以及预防和缓解DR的新型天然药物。
